UBS Group’s Apexigen, Inc. WarrantApexigen, Inc. Warrant APGNW Stock Holding History

UBS Group’s Portfolio APGNW Stock Details APGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,094	Closed	-$105	–	10271
2023 Q2	$105	Buy	3,094 +3,088	+51,467%	+$135	﹤0.01%	8502
2023 Q1	$0	Sell	6 -906	-99%	-$77	﹤0.01%	11067
2022 Q4	$27	Buy	+912	New	+$73	﹤0.01%	10538
2022 Q3	–	Sell	-8,453	Closed	-$1K	–	11338
2022 Q2	$1K	Buy	8,453 +5,198	+160%	+$861	﹤0.01%	10101
2022 Q1	$1K	Sell	3,255 -4,151	-56%	-$1.36K	﹤0.01%	10035
2021 Q4	$3K	Sell	7,406 -2,549	-26%	-$1.75K	﹤0.01%	9731
2021 Q3	$7K	Buy	+9,955	New	+$9.57K	﹤0.01%	8360
2021 Q2	–	Sell	-2,084	Closed	-$4K	–	10018
2021 Q1	$4K	Buy	+2,084	New	+$4.23K	﹤0.01%	8451

Other funds holding APGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

UBS Group's APGNW Position: Q3 2023 in Review

UBS Group sold out of Apexigen, Inc. WarrantApexigen, Inc. Warrant (APGNW) in Q3 2023, closing a stake of 3,094 shares — an estimated $105 sold.

UBS Group first reported a position in APGNW in Q1 2021 and held it in 8 quarters. The position peaked at $7K in Q3 2021. 1 fund tracked by Wall St. Rank holds APGNW as of Q3 2023.

UBS Group reported no remaining Apexigen, Inc. WarrantApexigen, Inc. Warrant position as of Q3 2023 after selling out during the quarter.
UBS Group sold 3,094 Apexigen, Inc. WarrantApexigen, Inc. Warrant shares in Q3 2023, an estimated $105.
UBS Group first reported a position in Apexigen, Inc. WarrantApexigen, Inc. Warrant in Q1 2021 and held it in 8 quarters.
UBS Group's Apexigen, Inc. WarrantApexigen, Inc. Warrant position peaked at $7K in Q3 2021.
1 fund tracked by Wall St. Rank held Apexigen, Inc. WarrantApexigen, Inc. Warrant as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.